Summary
This paper discusses the clinical implementation of enfortumab vedotin and pembrolizumab as the new first-line standard of care for advanced urothelial cancer, based on superior efficacy demonstrated in the EV-302 phase 3 trial. The authors emphasise the importance of clinical judgement in patient selection and management, noting that the combination's distinct toxicity profile warrants consideration of baseline clinical parameters despite current guideline inclusion without specific restrictions. The work addresses a gap between trial evidence and real-world clinical practice in oncology.
UK applicability
As this is a clinical oncology paper not related to agricultural or food systems research, it has no direct applicability to UK farming, soil health, or food production domains. It may inform NHS commissioning and clinical guidance for urothelial cancer treatment.
Key measures
Overall response rate, progression-free survival, overall survival, and toxicity profiles (skin rash and neuropathy)
Outcomes reported
The study examined clinical decision-making regarding the use of enfortumab vedotin and pembrolizumab (EVP) combination therapy in first-line advanced urothelial cancer treatment, considering baseline clinical parameters and toxicity management.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.